AMPK activation: a therapeutic target for type 2 diabetes?

Código QR

AMPK activation: a therapeutic target for type 2 diabetes?

Kimberly A Coughlan, Rudy J Valentine, Neil B Ruderman, Asish K Saha Endocrinology and Diabetes, Department of Medicine, Boston University Medical Center, Boston, MA, USA Abstract: Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell dysfunction, and el...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Coughlan KA, Valentine RJ, Ruderman NB, Saha AK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/ef61d514b1eb41c3b14a4bfaab5498d9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
por: Michael A Via, et al.
Publicado: (2010)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
por: Seufert J
Publicado: (2015)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review
por: Katrine B Hansen, et al.
Publicado: (2010)

Saxagliptin for type 2 diabetes
por: Antonio R Chacra, et al.
Publicado: (2010)

Sexual dysfunction in diabetic women: prevalence and differences in type 1 and type 2 diabetes mellitus
por: Mazzilli R, et al.
Publicado: (2015)

Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
por: Kedia N
Publicado: (2011)

Impact of physical activity and bodyweight on health-related quality of life in people with type 2 diabetes
por: Eckert K
Publicado: (2012)

Type 2 diabetes in Brazil: epidemiology and management
por: Almeida-Pititto B, et al.
Publicado: (2015)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
por: Whaley JM, et al.
Publicado: (2012)

Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes
por: Mackenzie RWA, et al.
Publicado: (2014)

Disturbance of inorganic phosphate metabolism in diabetes mellitus: temporary therapeutic intervention trials
por: J&oslash;rn Ditzel, et al.
Publicado: (2009)

Linking obesity with type 2 diabetes: the role of T-bet
por: Wali JA, et al.
Publicado: (2014)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
por: Rigato M, et al.
Publicado: (2014)

Risk management in the treatment of type 2 diabetes with pioglitazone
por: Giuseppe Derosa, et al.
Publicado: (2009)

Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor
por: Zheng X, et al.
Publicado: (2015)

Expression of gluconeogenic enzymes and 11β-hydroxysteroid dehydrogenase type 1 in liver of diabetic mice after acute exercise
por: Brust KB, et al.
Publicado: (2014)

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
por: Gregory E Peterson
Publicado: (2009)

Evidence for the benefit of exercise therapy in patients with type 2 diabetes
por: Madden KM
Publicado: (2013)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander PA
Publicado: (2012)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Shannon A Miller, et al.
Publicado: (2009)

Red cell distribution width in type 2 diabetic patients
por: Nada AM
Publicado: (2015)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
por: Robert Moses
Publicado: (2009)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Pamela Kushner
Publicado: (2010)

Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
por: Henri K Parson, et al.
Publicado: (2010)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Joshua J Neumiller, et al.
Publicado: (2010)

Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia
por: Anderson M, et al.
Publicado: (2014)

Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
por: Sosale A, et al.
Publicado: (2015)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto M
Publicado: (2013)

Sex differences in type 2 diabetes: focus on disease course and outcomes
por: Arnetz L, et al.
Publicado: (2014)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud A, et al.
Publicado: (2015)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz B
Publicado: (2013)

Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation
por: Dara P Schuster
Publicado: (2010)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Bo Ahr&eacute;n
Publicado: (2010)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holl, et al.
Publicado: (2014)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Jonathan K Reynolds
Publicado: (2009)

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
por: Nishio S, et al.
Publicado: (2015)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Stanley S Schwartz
Publicado: (2010)

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
por: Feher M, et al.
Publicado: (2013)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto S, et al.
Publicado: (2015)

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
por: Paul Valensi
Publicado: (2009)